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Volume 52, Number 2 Letters to the Editor 535resection of the involved layers of the popliteal wall was performed
(Fig 2). She had an uneventful recovery, without walking impair-
ment afterwards.
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We readwith interest the letter to the editor regarding our article
“High spatial resolutionmagnetic resonance imaging of cystic adven-
titial disease of the popliteal artery.”1 As the title implies, we reported
the (never before published) use of a novel magnetic resonance (MR)
technique, high spatial resolutionmagnetic resonance imaging (MRI)
in three patients with cystic adventitial disease (CAD).
The MR technique used in our cases provides a far higher
spatial resolution than MR techniques reported in previous MRI
publications on CAD. The voxel size of 0.4  0.4  0.7 mm
achieved in our work allowed us to detect even very small commu-
nications between the adventitial cysts and the joint space, such as
the one shown in our Fig 1, E. By our estimates, the spatial
resolution of our technique is 10 to 30 times higher than the one
achieved in the Crolla and Chiche reports.2,3
The focus of our article was not the description of the MRI
features of CAD, something that indeed has been described previ-
ously. Rather, we report the use of a novel, high spatial resolution
MRI technique that enabled us to detect these communications in
all our patients. We are therefore somewhat surprised that the
authors “doubt the value” of our study. We do congratulate them
however on the successful surgical treatment and ultrasonographic
diagnosis of their CAD patient. We believe that high spatial reso-
lution MRI reliably allows the detection of connections between
adventitial cysts and adjacent joints in CAD patients and thus has
the potential to diminish postsurgical CAD recurrence rates.
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Regarding “Serum carboxymethyllysine
concentrations are reduced in diabetic men with
abdominal aortic aneurysms: Health In Men Study”
We have read with great interest the article of Norman et al1 in
the Journal of Vascular Surgery dealing with serum carboxymeth-
yllysine (CML) concentrations in diabetic men with abdominal
aortic aneurysms. CML belongs to the group of advanced glyca-
tion end products (AGEs) and has been associated with the devel-
opment of atherosclerosis. AGE concentrations are increased in
diabetes and are related to arterial stiffness. Tissue accumulation of
AGEs leads to cross-linking of proteins, for example, within the
vessel wall, which may lead to increased arterial stiffness. Norman
et al hypothesize that AGEs may be partly responsible for the
observed inverse association between abdominal aortic aneurysm
and diabetes. Indeed, they observed lower serum CML concentra-
tion in diabetic men with AAA than in those without. Several
questions remain after reading this article, however.
AGEs form a heterogeneous group in which some show
cross-linking properties, whereas others do not.2 In their study,
Norman et al only measured serum concentrations of the non-
cross-linking AGE CML. They did not measure concentrations of
cross-linking AGEs, such as pentosidine. Assessing concentrations
of cross-linking AGEs, such as pentosidine, seems more appropri-
ate to test their hypothesis that protein cross-linking reduces the
risk for developing AAAs. Furthermore, the authors cannot ex-
clude the possibility that other AGEs are related to the develop-
ment of AAAs. Zhang et al3 recently observed a 2.7-fold higher
accumulation of AGEs in human AAA tissue than in normal aortic
tissues. The expression of the multiligand receptor for AGEs
(RAGE) was also highly elevated in human AAA tissue. Increased
RAGE expression was associated with higher levels of matrix
metalloproteinases, an important mediator for aneurysmal devel-
opment.3
Tissue AGE concentrations are strongly related to the severity
of cardiovascular disease, whereas serum concentrations are often
not. High serum AGE levels, for example, were associated with a
better survival in hemodialysis patients.4 High tissue AGE concen-
trations in these patients, however, were strong predictors of death
and cardiac failure.5,6 Higher serum AGE levels were probably a
measure of a better nutritional support, associated with improved
survival. Serum AGE levels are strongly influenced by renal func-
tion, absorption from food, smoking, and medication use, such as
statins. It seems therefore appropriate to prefer assays of tissue
AGE accumulation rather than serum samples. In our opinion,
even after the elegant study from Norman et al, it remains unclear
whether AGEs play a role in causing or preventing aneurysmal
disease.
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Reply
The points made in the letter do not contradict our data. Ad-
vanced glycation end products (AGEs) are a heterogeneous group.
Non-carboxymethyllysine (CML) AGEs may influence the develop-
ment of abdominal aortic aneurysms (AAAs), and assessing concen-
trations of cross-linking AGEs like pentosidine will be important. We
did not claim that our study provided conclusive evidence—merely
that the data suggested that accelerated advanced glycation might
explain the inverse association between diabetes and AAA. We had
also acknowledged that othermarkers of the glycation pathwaywould
need to be examined in future studies.
The assessment of any putative biomarker at tissue level is
always desirable, and sometimes preferable. However, this is not
without problems in AAA, because only tissue samples from end-
stage disease (ie, large AAAs) with secondary degenerative changes
are available. Furthermore, such samples are becoming scarce due
to the increasing role of endoluminal stenting. We are also unsure
about whether the findings in the three cited studies in hemodial-
ysis patients are generalizable to the vast majority of patients with
normal or mildly impaired renal function.
Despite the acknowledged limitations of our study, CML is used
as a general and reproducible measure of glycation, and our data are
consistent with evidence that glycation of the extracellular matrix
inhibits degradationbothbydeactivatingmacrophages and increasing
the resistance of the extracellular matrix to degradation.1
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Regarding “Statins, heme oxygenase-1, iron, and
atherosclerosis”
DePalma et al1 described interactions of serum ferritin with
statin use in a substudy of the iron (Fe) and atherosclerosis study
(FeAST). At baseline, 53 participants on statins had slightly
lower mean entry-level ferritin values (1l4.06 ng/mL) vs the 47
off statins (127.62 ng/mL). Longitudinal analysis of follow-up
data, after adjusting for the phlebotomy treatment effect,
showed that statin use was associated with significantly lower
ferritin levels (–29.78 ng/mL; Cohen effect size, 0.47 [tdf,
134  2.33, P  .02]).
Statins induce heme oxygenase-1 (HO1)2,3 the rate limiting
enzyme involved in heme catabolism. Heme catabolism is a key
process in mobilizing macrophage iron derived from ingested
erythrocytes. Alterations in the activity of HO1 influence the rate
of clearance of hemoglobin-derived iron from macrophages. Phar-
macologic inhibition of HO1 is associated with marked elevation
in serum ferritin without significant changes in several other acute
phase reactants.4 In normal subjects, serum ferritin rose by approx-
imately fourfold within 2 days of administration of Sn mesopor-
phyrin, an HO1 inhibitor.4
In the HO1 deficient mouse (HO1/), conspicuous iron
loading is seen in Kupffer cells, hepatocytes, hepatic vascular
tissue, and renal cortical tubules.5 In another study of
HO1/ mice, increased levels of reactive oxygen species
production in macrophages and increased atherosclerotic
plaque were thought to be a result of relatively decreased
intracellular levels of biliverdin or bilirubin, or increased intra-
cellular levels of iron stores.6
In diabetic humans, HO1 promoter polymorphisms caus-
ing weaker upregulation of the enzyme are associated with both
increased cardiovascular disease and significantly increased se-
rum ferritin.7,8 It has been proposed that statins may stabilize
atherosclerotic plaques in part by inducing intralesional HO1,
facilitating iron mobilization, and lowering plaque iron lev-
els.9,10 The findings of DePalma et al1 are compatible with this
proposed mechanism.
Statins have also been reported to lower interleukin-6
(IL-6) concentrations.11 IL-6 is a potent inducer of hepcidin
which favors iron retention in the macrophage. This effect of
statins is another potential mechanism for lowering iron levels in
plaque macrophages, a process proposed to inhibit atherogen-
esis.10
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